|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS |
Jun 2020 |
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Jun 2020 |
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
Jun 2020 |
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: Moving Towards Personalized Management |
May 2020 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions |
May 2020 |
Haematologica |
Aplastic Anemia |
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
May 2020 |
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
